Ignite Creation Date:
2024-05-05 @ 9:36 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002155
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Six-Month Safety and Antiviral Study in HIV-1 Seropositive AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cellsmm3 to Evaluate MK-639 Alone Versus Zidovudine AZT and 3TC Versus the Combination of MK-639 With AZT3TC
Sponsor:
Merck Sharp Dohme LLC
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Six-Month Safety and Antiviral Study in HIV-1 Seropositive AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cellsmm3 to Evaluate MK-639 Alone Versus Zidovudine AZT and 3TC Versus the Combination of MK-639 With AZT3TC
Status:
COMPLETED
Status Verified Date:
1996-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare effects on CD4 counts and serum viral RNA among HIV-seropositive zidovudine AZT-experienced patients in three treatment arms indinavir sulfate MK-639 Crixivan plus AZT plus lamivudine 3TC versus MK-639 alone versus AZT3TC
Detailed Description:
AZT-experienced patients are randomized to receive MK-639AZT3TC or MK-639 alone or AZT3TC Additionally patients who have received 6 months of AZT or who are intolerant but received prior 3TC or who require concomitant rifampin therapy may receive open-label MK-639
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 039 | None | None | None |